Celldex Therapeutics Announcement
Celldex Therapeutics (CLDX) announced today preclinical data from its CDX-622 bispecific antibody with dual targeting of the alarmin TSLP and stem cell factor (SCF), also known as KIT receptor ligand, developed from its bispecific antibody platform.

TSLP and SCF demonstrated their contribution to the pathophysiology of various inflammatory, fibrotic and allergic disorders.

The data . . .